> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Covid-19 Blood Purification System Gets EUA
- URL: https://www.fdaweb.com/covid-19-blood-purification-system-gets-eua/
- Published: 2020-04-10T12:00:00.000Z
- Updated: 2026-09-14T16:10:56.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5146542

FDA has issued an [emergency use authorization](https://www.fda.gov/media/136834/download?ref=fdaweb.com) to Terumo BCT and Marker Therapeutics for their Spectra Optia Apheresis System and Depuro D2000 Adsorption Cartridge devices that serve as a blood purification system to treat patients with confirmed Covid-19 admitted to the intensive care unit with confirmed or imminent respiratory failure. The product works by filtering blood to reduce the amount of cytokines and other inflammatory mediators, an [agency release](http://s2027422842.t.en25.com/e/es?s=2027422842&e=321220&elqTrackId=376c7bc788024cd5a73d955f2e3dcbdc&elq=6a4a99e485d4477bb6b32e5dfea43581&elqaid=12041&elqat=1&ref=fdaweb.com) says. “The proteins that are removed are typically elevated during infections and can be associated with a ‘cytokine storm’ that occurs in some Covid-19 patients, leading to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death,” it says.